CEO Occlutech Memenangkan Gugatan Paten yang Diajukan oleh St Jude-AGA Medical

AsiaNet 46504

JENA, Jerman, 26 September /PRNewswire-AsiaNet/ —

Occlutech, pengembang implan terkemuka di Eropa untuk mengobati penyakit
jantung struktural, hari ini mengumumkan bahwa CEO-nya, Bapak Tor Peters,
memperoleh putusan yang menguntungkan dari pengadilan wilayah di Duesseldorf
dalam litigasi (proses hukum) paten yang diajukan sendiri terhadapnya oleh St
Jude AGA Medical.

Pada tanggal 10 Mei 2011, Occlutech GmbH memenangkan gugatan paten berumur
lebih dari 5 tahun yang diajukan oleh St Jude-AGA Medical di Pengadilan Tinggi
Jerman di Karlsruhe terkait pelanggaran paten EP 808 138.

Dalam proses lebih lanjut di Pengadilan Wilayah di Duesseldorf, St
Jude-AGA Medical menuduh CEO Occlutech GmbH, Bapak Tor Peters, secara pribadi
atas dugaan pelanggaran paten EP 808 138. Dalam putusan bertanggal 8 September
2011, klaim ini juga telah ditolak oleh Pengadilan Wilayah di Duesseldorf.
Putusan ini tengah diajukan banding oleh St Jude-AGA Medical.

Tor Peters berkata: “Sungguh menakjubkan dan mengejutkan melihat
perusahaan yang biasanya Anda anggap etis, melakukan langkah yang mencoba
mengalahkan pesaingnya secara pribadi dengan litigasi yang sangat besar dan
dibenarkan. Tentu saja kami merasa sangat senang bahwa pengadilan di Jerman
kini memutuskan permohonan kami sebagaimana telah dilakukan oleh pengadilan di
Inggris, Belanda, dan Swedia sebelumnya.”

Perangkat oklusi digunakan untuk mengobati penyakit jantung struktural,
termasuk cacat dan kelainan jantung struktural seperti Atrial Septal Defects,
(ASD), dan Patent Foramen Ovale (PFO, saluran yang tidak seharusnya ada di
antara dua arteri jantung, yang dialami sebanyak lebih dari 25% populasi),
dalam prosedur tanpa pembedahan yang memerlukan sedikit tindakan. Pasar
occluder PFO diharapkan akan meluas secara signifikan karena hubungan antara
PFO dan stroke, yang merupakan penyebab kematian terbesar ketiga, serta migren
parah dapat semakin didokumentasikan dengan baik.

SUMBER: Occlutech GmbH


Occlutech CEO Wins Patent Lawsuit by St Jude-AGA Medical

JENA, Germany, Sept. 26 /PRNewswire-AsiaNet/ —

Occlutech, a leading European developer of implants for treating structural heart disease today announced that its CEO, Mr Tor Peters, has obtained a favorable ruling from the district court in Duesseldorf in patent litigation initiated personally against him by St Jude AGA Medical.

On the 10th of May 2011, Occlutech GmbH won an over 5 years long patent lawsuit initiated by St Jude-AGA Medical at the German Supreme Court in Karlsruhe regarding infringement of patent EP 808 138.

In further proceedings at the Regional Court in Duesseldorf, St Jude-AGA Medical accused the CEO of Occlutech GmbH, Mr Tor Peters, privately for alleged violation of patent EP 808 138. In a ruling dated September 8th 2011, this claim has now also been rejected by the District Court in Duesseldorf. The ruling is subject to appeal by St Jude-AGA Medical.

Tor Peters says; “It is amazing and quite shocking to see a company that you would normally consider ethical, going to such length in trying to kill a competitor by also going after private individuals with this kind of massive and unjustified litigation. Obviously we are very happy that the courts in Germany now ruled in our favor as courts in The UK, The Netherlands and Sweden have done before.”

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart’s two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

SOURCE: Occlutech GmbH